Day 3 Agenda

April 18, 2024

The information presented in this publication, including but not limited to the 2024 SDP Annual Conference agenda, is subject to change without prior notice. While every effort has been made to ensure the accuracy and timeliness of the details provided, unforeseen circumstances, scheduling adjustments, or other factors beyond our control may impact the final agenda.

Attendees are advised to regularly check the official conference website, communication channels, and announcements for the most up-to-date information. SDP reserves the right to modify, add, or remove sessions, speakers, or any other aspects of the conference program as deemed necessary.

Pre Active.png
Day1 Inactive.png
Day2 Inactive.png
Day3 Active.png
Post Inactive.png

Session 1

Yellow.png

April 18, 2024

Speaker: Brendon Keinath (RWE Offshore Wind US)

Abstract:

In 2021, the Biden-Harris administration set a goal of deploying 30 gigawatts of offshore wind by 2030 and 110 gigawatts by 2050. The first commercial scale wind farms in the US are currently being installed off the East Coast and the industry is at a fever pitch. That said, there is still a significant amount of uncertainty around achieving these goals several decades out. In this case study, Decision Quality methods in Scenario Thinking were applied to understand key drivers (e.g., political, technical, supply chain, etc.) and develop future worlds to gain insights for circumstances where these goals are exceeded, met or missed in order to inform future planning.

more

April 18, 2024

Speaker: Sri Vaidyanathan (Shell)

Abstract:

Global energy supply chains, historically driven by financial efficiency whose fragility was brought to focus during the pandemic. The pandemic and supply chain chokes of the recent years has exposed the vulnerability of these supply chains. Considered together with the need for decisive actions towards a net-zero future, structure and priorities within global supply chains are in urgent need of reconsideration.

Supply chains are essentially networks of various organizations, including suppliers, manufacturers, and retailers, aiming to deliver products or services to the end consumer. When these products cross multiple international boundaries like in complex-energy supply chains, the chain becomes global, bringing about interdependencies among the organizations.

While the laser focus on financial efficiency has offered benefits in the past, changing...

more
Orange.png

Case Study

April 18, 2024

Speaker: Dr. Hong Yang (FDA, Center for Drug Evaluation and Research)

Abstract:

Medical product decision-making at FDA is a complex process involving large, multi-disciplinary teams, voluminous streams of scientific information, regulatory requirements, and diverse external stakeholders. Focusing on Agency decision-making at the time of initial marketing authorization, this session will provide an overview of the principles of benefit-risk assessment used by the three medical product centers and demonstrate how benefit-risk assessment, a subset of decision analysis, informs regulatory decision-making. Illustrative case examples showing the spectrum of decision analysis approaches used will be provided as well as information useful to product sponsors. Dr. Lackey from the Center for Drug Evaluation and Research (CDER), will provide an overview of the descriptive Benefit-Risk Framework for new drug approval...

more

April 18, 2024

Speaker: Leila Lackey (FDA, Center for Drug Evaluation and Research)

Abstract:

Medical product decision-making at FDA is a complex process involving large, multi-disciplinary teams, voluminous streams of scientific information, regulatory requirements, and diverse external stakeholders. Focusing on Agency decision-making at the time of initial marketing authorization, this session will provide an overview of the principles of benefit-risk assessment used by the three medical product centers and demonstrate how benefit-risk assessment, a subset of decision analysis, informs regulatory decision-making. Illustrative case examples showing the spectrum of decision analysis approaches used will be provided as well as information useful to product sponsors. Dr. Lackey from the Center for Drug Evaluation and Research (CDER), will provide an overview of the descriptive Benefit-Risk Framework for new drug approval...

more

April 18, 2024

Speaker: Dr. David Gebben (FDA, Center for Drug Evaluation and Research)

Abstract:

Medical product decision-making at FDA is a complex process involving large, multi-disciplinary teams, voluminous streams of scientific information, regulatory requirements, and diverse external stakeholders. Focusing on Agency decision-making at the time of initial marketing authorization, this session will provide an overview of the principles of benefit-risk assessment used by the three medical product centers and demonstrate how benefit-risk assessment, a subset of decision analysis, informs regulatory decision-making. Illustrative case examples showing the spectrum of decision analysis approaches used will be provided as well as information useful to product sponsors. Dr. Lackey from the Center for Drug Evaluation and Research (CDER), will provide an overview of the descriptive Benefit-Risk Framework for...

more
Black.png

Personal & Societal Decisions

April 18, 2024

Speaker: Eric Johnson (GSK)

Abstract:

We often have many objectives when we face big personal decisions like buying a house or car. If the information and judgments are all available, the basic data and logic for a multi-objective analysis can be captured in a simple grid in a spreadsheet. But if we are in an iterative process of information framing and gathering, the considerations and links to source data may get lost in the shuffle (leading to rework), and the tool may not give high-level insights (leading to poorly focused investigation). In this talk, I show some design ideas for a MODA spreadsheet that address these issues, with examples from my own house and car purchase decisions.

more

April 18, 2024

Co-Chairs: Amy Day (Clarity4Action.Org) & Chris Spetzler (Decision Education Foundation)

Panel: Steve Begg (The University of Adelaide), Terry Karner (Astellas), Kuno Huisman (ASML)

Abstract:

Decision Professionals know the value of DQ in their own lives and careers, yet many would like to help others learn these effective tools. This session will bring together Decision Professionals who have acted...

more

Session 2

Yellow.png

April 18, 2024

Speaker: George Nsoribe (Chevron)

Abstract:

With the global clamor for lower carbon emissions, huge volatility in oil market prices, cost of exploration and production, technology changes and political factors in regions where oil is found in commercial quantities, the near- permanent pseudo war between USA and China to the actual war in Eastern Europe, It’s the dawn of a new era in the energy industry and realizing it can no longer be business as usual, industry chiefs need to transform themselves and their organizations to succeed. To further call out the situation, in 2015 the United Nations (UN) developed a set of sustainable development goals, one of which was to ensure access to affordable, reliable, sustainable, and modern energy for all by 2030 with one of the targets being to increase substantially the share of renewable energy in the global energy mix by then. This target puts pressure on country...

more

April 18, 2024

Speaker: Carl Spetzler (Strategic Decisions Group)

Abstract:

Large Capital Projects present unique challenges that are being addressed with IPD (Integrated Project Delivery). Full adoption and integration of DQ within IPD assures maximum value in large projects. The organizational transformation needs are unique since project organizations are in constant transition throughout the project life cycle. We will review what it takes to achieve success in this transformation.

more
Orange.png

April 18, 2024

Speaker: Michael Kane (Telperian)

Abstract:

Accurate valuations of both pre- and post-revenue drug assets plays an instrumental role in a broad range of operations and decisions the biotechnology and pharmaceutical sectors.They inform decisions made not only by pharmaceutical companies but also by a range of stakeholders including venture capitalists, private equity firms, and others. An accurate valuation provides a reliable forecast of the potential return on investment, which directly influences where and how capital is allocated within the industry. It forms the basis of strategic investment decisions, making it possible to identify the most promising opportunities and understand which investments are more likely to yield a satisfactory return. In this talk we present models designed to estimate future sales of post-revenue and pre-revenue assets. The former generates distributional estimates of each asset’s...

more

April 18, 2024

Speaker: Paul Gordon (Catalyze)

Abstract:

This presentation will show how an MCDA decision modelling approach, coupled with a collaborative process was used to determine and understand the range and extent of harms that 23 drugs has across New Zealand. The drug harms were evaluated by a diverse group of experts and considered both the whole-of-population harms and harms specific to youth (12-17 years old) across 17 distinct harms. The harms considered covered both harms to the user, and harms to others around the user.

The background and history of the approach and methodology will be presented, including a summary of a similar earlier study in Australia, and will explore how this approach could provide valuable insights into how to think about drug harms in general.

more

April 18, 2024

Speaker: Niki Arya (AstraZeneca)

Abstract:

We utilized expert elicitation to determine the prior assumptions needed to calculate the probability of technical success (PTS) for a planned large outcome study. The primary endpoint for the large outcome study is a composite endpoint with subcomponents that are major events (deaths, hospitalizations, etc.). A presentation was put together summarizing the results from previous trials with our drug and other drugs within the same medication class. In these trials, a similar composite endpoint and the individual subcomponents were analyzed in slightly different populations to help shape prior assumptions about the effects of our drug on the primary endpoint proposed in our large outcome study. This presentation was shared with a panel of 5 experts in this field who then used these results to predict the expected treatment effect on the primary composite endpoint and...

more
Black.png

Algorithmically-Aided Decision Making

April 18, 2024

Speaker: Fadi Micaelian (Sparkdit)

Abstract:

We will explore in this use case how the leading aviation and aerospace giant was able to solve the problem of airplane swapping by dynamically optimizing their business objectives: Traveler Satisfaction, Airline Revenue, and Airline Expenses. The problem could not be tackled with traditional AI alone as it lacked both causality and the ability of taking into account the constantly changing market needs and requirements. We will also briefly touch on how the same AI augmentation technology, rooted in Decision Science, is yielding 2x better eCommerce recommendations than Content Filtering, or AI based Collaborative Filtering, without ever intruding on consumer privacy.

more

April 18, 2024

Speaker: Patrick Elder (ECS Federal)

Abstract:

In the era of Artificial Intelligence (AI) and machine learning, decision makers and decision analysts can be caught between the desire to leverage new technologies and the seemingly inherent opacity that comes with complex models. Without the ability to explain and ultimately justify the decision based on the results from AI models, these end-users can feel like passengers on a journey without a clear understanding of the route or destination. However, the advent of Explainable AI (XAI) promises to transform this landscape by providing transparency and interpretability in AI systems.

This session briefing at the Society of Decision Professionals Conference will delve into the thought-provoking article titled "Explainable AI: How XAI Puts the End User Back in the Driver's Seat" (...

more

Session 3

Yellow.png

Case Study

April 18, 2024

Speaker: Heather Stang (Aera Energy)

Abstract:

The oil and gas industry in California is challenged due to the ever-changing regulatory environment at the state and county level, resulting in a near-term hiatus in new well and workover permitting. To continue value generation, operators must rapidly adapt their strategies to this shifting landscape and refocus on brownfield optimization. A value of information approach is being utilized in an attempt to align value metrics across functional business units to generate the highest return on investments.

more
Orange.png

Round Table Discussion

Black.png

New Perspectives on DQ

April 18, 2024

Speaker: Bill Haskett (Haskett Consulting International)

Abstract:

Do you really have a strategy? Strategy development and implementation support is a different flavour of decision support from that provided within most projects. While our Decision Quality principles remain intact, a shift that emphasizes greater context, positioning, and pathway/vehicle is required. The Objective emphasis shifts to access, materiality, positioning, control, and preservation. Hambrick and Fredrickson developed an excellent approach to strategy development in the early 2000’s citing five components (Location, Vehicles, Staging, Differentiation, and Economic Logic) but it deserves updating from our decision and facilitation perspective. As guides to strategy development, we must ensure a greater emphasis on effective implementation. For example, it isn’t good enough to only differentiate. Competitive advantage (offensive and...

more

April 18, 2024

Speaker: Patrick Leach (Independent Strategy Consultant)

Abstract:

The goal of sustainability efforts is to strike the right balance between two competing objectives: meeting the needs of the current population, and allowing (or even enhancing) the ability of future populations to meet their needs. Using economic metrics to decide what sustainability initiatives to pursue undermines this objective for several reasons. First, all commonly used economic metrics are maximized by pulling as many benefits as far forward in time as possible, and pushing as many costs as far into the future as possible. They are thus strongly biased toward enjoying ourselves today at the expense of tomorrow.

Second, our entire system of free-market economics is driven by growth – ever-increasing consumption of resources (GDP growth) and an ever-larger human population (witness economists fretting over the drop in fertility...

more

April 18, 2024

Speaker: Sheldon Bernard (A440 Management)

Abstract:

This conversation focuses on elucidating the fundamental role of the Bayesian framework in decision analysis, a crucial discipline and toolkit for navigating decision-making under uncertainty. Tracing back to our roots, we aim to unfold the connection between Bayesian Decision Theory and Inference and its relation to Decision Analysis. By offering thought-provoking insights (via case study) into the broader picture and practical applications of Bayesian Inference, we extend our exploration to its capacity for solving complex business problems with data. We will discuss how the Bayesian foundation provides the path to integrate Behavioral Economics, Decision Analysis, and Data Science. The aim is to provide perspective on how a Bayesian framework can help equip decision-makers with strategies to diminish bias and augment decision quality.

more

Networking.png

Interactive Session

April 18, 2024

Pre Active.png
Day1 Inactive.png
Day2 Inactive.png
Day3 Active.png
Post Inactive.png

Conference Sponsors

SILVER SPONSOR

BRONZE SPONSOR

Q&A SPONSOR

SUPPORTING LEVEL